최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Korean journal of clinical laboratory science : KJCLS = 대한임상검사과학회지, v.49 no.4, 2017년, pp.446 - 454
박선영 (연세대학교 임상병리학과) , 윤현석 (옵티팜 엠엔디) , 방혜은 (연세대학교 임상병리학과) , 김연 (연세대학교 임상병리학과) , 최성경 (옵티팜 엠엔디) , 안성우 (연세대학교 임상병리학과) , 김정호 (연세대학교 임상병리학과) , 이수지 (연세대학교 임상병리학과) , 양지영 (연세대학교 임상병리학과) , 이동섭 (혜전대학교 임상병리과)
Human papillomaviruses (HPVs) are major causes of cervical cancer. Sixteen high risk HPVs, including HPV 16, HPV 18, HPV31, HPV 33, HPV 35, HPV 39, HPV 45, HPV 51, HPV 52, HPV 53, HPV 56, HPV 58, HPV 59, HPV 66, HPV 68, and HPV 69 are found in cervical cancer. HPVs 16 and 18 are mainly presented in ...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12-23.
Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-527.
Kjaer SK, Munk C, Junge J, Iftner T. Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention? Cancer Causes Control. 2014;25(2):179-189.
Castle PE, Jeronimo J, Temin S, Shastri SS, et al. Screening to prevent invasive cervical cancer: ASCO resource-stratified clinical practice guideline. J Clin Oncol. 2017;35(11):1250-1252.
Castle PE, Katki HA. Benefits and risks of HPV testing in cervical cancer screening. Lancet Oncol. 2010;11(3):214-215.
Herbert A. Primary HPV testing: a proposal for co-testing in initial rounds of screening to optimise sensitivity of cervical cancer screening. Cytopathology. 2017;28(1):9-15.
Min KJ, Lee YJ, Suh M, Yoo CW, Lim MC, Choi J, et al. The Korean guideline for cervical cancer screening. J Gynecol Oncol. 2015;26(3):232-239.
Lee JK, Hong JH, Kang S, Kim DY, Kim BG, Kim SH, et al. Practice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition. J Gynecol Oncol. 2013;24(2):186-203.
Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, et al. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer. J Clin Microbiol. 2010;48(8):2779-2785.
Park SM, Lee SK, Kim YS. Inhibition of cervical cancer cell growth by gene silencing of HPV16 E6 Induced by short-interfering RNA. Korean J Clin Lab Sci. 2011;43(3):89-97.
Thomas M, Pim D, Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene. 1999; 18(53):7690-7700.
Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393(6682):229-234.
Caldeira S, Dong W, Tommasino M. Analysis of E7/Rb associations. Methods Mol Med. 2005;119:363-379.
Munkhdelger J, Kim GH, Wang HY, Lee DS, Kim SH, Choi YI, et al. Performance of HPV E6/E7 mRNA RT-qPCR for screening and diagnosis of cervical cancer with Thinprep pap test samples. Exp Mol Pathol. 2014;97(2):279-284.
Kim JH, Wang HY, Kim SY, Park SD, Yu KM, Kim HY, Uh Y, Lee HY. Evaluation of the Punch- $it^{TM}$ NA-Sample kit for detecting microbial DNA in blood culture bottles using PCR-reverse blot hybridization assay. Journal of Microbiological Methods. 2016; 128:24-30.
Walsh PS, Metzger DA, Higuchi R. Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. Biotechniques. 1991;10(4):506-513.
Mincheva A, Gissmann L, zur Hausen H. Chromosomal integration sites of human papillomavirus DNA in three cervical cancer cell lines mapped by in situ hybridization. Med Microbiol Immunol. 1987;176(5): 245-256.
Terry G, Ho L, Londesborough P, Cuzick J, Mielzynska-Lohnas I, Lorincz A. Detection of high-risk HPV types by the hybrid capture 2 test. J Med Virol. 2001;65(1):155-162.
Du Chateau BK, Schroeder ER, Munson E. Clinical laboratory experience with cervista HPV HR as a function of cytological classification: comparison with retrospective digene HC2 high-risk HPV DNA test data. J Clin Microbiol. 2013;51(3): 1057-1058.
Zhou F, Pulinthanathu R, Elgert P, Cangiarella J, Simsir A. Sensitivity of high-risk HPV Hybrid Capture II (hrHPV HC2) test using SurePath(TM) specimens in the prediction of cervical high-grade squamous lesions. Diagn Cytopathol. 2015;43(5): 381-387.
Huijsmans CJ, Geurts-Giele WR, Leeijen C, Hazenberg HL, van Beek J, de Wild C, et al. HPV prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and aptima workflows. BMC Cancer. 2016;16:922.
Kash N, Lee MA, Kollipara R, Downing C, Guidry J, Tyring SK. Safety and efficacy data on vaccines and immunization to human papillomavirus. J Clin Med. 2015;4(4):614-633.
Yang A, Farmer E, Wu TC, Hung CF. Perspectives for therapeutic HPV vaccine development. J Biomed Sci. 2016;23:75.
Kim TJ, Jin HT, Hur SY, Yang HG, Seo YB, Hong SR, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 Patients. Nat Commun. 2014;30:5317.
Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebocontrolled phase 2b trial. Lancet. 2015;386(10008):2078-2088.
Morrow MP, Kraynyak KA, Sylvester AJ, Shen X, Amante D, Sakata L, et al. Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100. Mol Ther Oncolytics. 2016;3:16025.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.